Skip to main content
Kristie A Bobolis, M.D.

Kristie A Bobolis, M.D.

Kristie Bobolis, MD, is a board‑certified hematologist and medical oncologist with more than three decades of experience advancing breast cancer care, clinical research, and multidisciplinary oncology practice. She completed her medical degree at the University of California, Irvine, followed by an internal medicine residency at UCLA and a hematology/oncology fellowship at Duke University.

Dr. Bobolis serves with Sutter Medical Group, where she is the longtime Medical Director of the Breast Cancer Program and Founding Medical Director of both the Clinical Cancer Genetics and Lymphedema Programs at Sutter Roseville Medical Center. A nationally recognized leader, she has held prominent roles within the National Consortium of Breast Centers, including serving as President from 2017–2019.

Dr. Bobolis is a treating investigator for NCI‑sponsored clinical trials and has contributed to high‑impact research published in Cancer Discovery, Nature Genetics, JAMA, and other leading journals. She is widely regarded for her commitment to patient‑centered, evidence‑driven cancer care.

In addition, Dr. Bobolis serves as Program Director of the ACGME accredited Hematology-Oncology Fellowship Program at Sutter Roseville Medical Center. The program will welcome its inaugural fellowship class in August 2026.

Research studies

Clinical trials

  • A Phase III Trial of Rx Therapy Guided by Genomic Risk Assessment for High Anatomic Stage ER-pos/HER2-neg Breast Cancer With RS≤25 (RxFINE-Low)

    Status: Open to Enrollment

  • A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)

    Status: Open to Enrollment

  • Randomized Phase II/III Trial of First Line Platinum/Etoposide With or Without Atezolizumab (NSC#783608) in Patients With Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)

    Status: Open to Enrollment

  • Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for MammaPrint Ultrahigh (PM2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer

    Status: Open to Enrollment

You're leaving our site

The website you have selected is an external one located on another server. This website may contain links to third party sites. These links are provided for convenience purposes and are not under the control of Sutter Health. Do you wish to continue?